Because of the probable role of HIV-infected monocyte/macrophages in the pathogenesis and progression of AIDS, it is essential that antiretroviral therapy address viral replication in cells of this lineage. Several dideoxynucleosides have been shown to have potent in vitro and, in the case of 3'-azido-2',3'-dideoxythymidine (AZT) and 2',3'-dideoxycytidine (ddC), in vivo activity against HIV. However, because these compounds must be phosphorylated (activated) in target cells, and because monocyte/macrophages may have levels of kinases that differ from those in lymphocytes, we investigated the capacity of these drugs to suppress HIV replication in monocyte/macrophages using HIV-1/HTLV-IIIBa-L (a monocytotropic isolate). In the present study, we observed that HTLV-IIIBa-L replication in fresh human peripheral blood monocyte/macrophages was suppressed by each of three dideoxynucleosides: 3'-azido-2',3'-dideoxythymidine (AZT), 2',3'-dideoxycytidine (ddC), and 2',3'-dideoxyadenosine (ddA). Similar results were observed in 5-d-cultured monocyte/macrophages, although higher concentrations of the drugs were required. We then studied the metabolism of AZT and ddC in such cells. The phosphorylation of ddC to a triphosphate moiety was somewhat decreased in monocyte/macrophages as compared with H9 T cells. On the other hand, the phosphorylation of AZT in monocyte/macrophages was markedly decreased to 25% or less of the level in T cells. However, when we examined the level of the normal endogenous 2'-deoxynucleoside triphosphate pools, which compete with 2',3'-dideoxynucleoside triphosphate for viral reverse transcriptase, we found that the level of 2'-deoxycytidine-triphosphate (dCTP) was six- to eightfold reduced, and that of 2'-deoxythymidine-triphosphate (dTTP) was only a small fraction of that found in T cell lines. These results suggest that the ratio of dideoxynucleoside triphosphate to normal deoxynucleoside triphosphate is a crucial factor in determining the antiviral activity of dideoxynucleosides in HIV target cells, and that the lower levels of dTTP may account for the antiretroviral activity of AZT in the face of inefficient phosphorylation of this compound.
Article|
September 01 1988
Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides.
C F Perno,
C F Perno
Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland 20892.
Search for other works by this author on:
R Yarchoan,
R Yarchoan
Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland 20892.
Search for other works by this author on:
D A Cooney,
D A Cooney
Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland 20892.
Search for other works by this author on:
N R Hartman,
N R Hartman
Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland 20892.
Search for other works by this author on:
S Gartner,
S Gartner
Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland 20892.
Search for other works by this author on:
M Popovic,
M Popovic
Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland 20892.
Search for other works by this author on:
Z Hao,
Z Hao
Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland 20892.
Search for other works by this author on:
T L Gerrard,
T L Gerrard
Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland 20892.
Search for other works by this author on:
Y A Wilson,
Y A Wilson
Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland 20892.
Search for other works by this author on:
D G Johns
D G Johns
Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland 20892.
Search for other works by this author on:
C F Perno
Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland 20892.
R Yarchoan
Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland 20892.
D A Cooney
Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland 20892.
N R Hartman
Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland 20892.
S Gartner
Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland 20892.
M Popovic
Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland 20892.
Z Hao
Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland 20892.
T L Gerrard
Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland 20892.
Y A Wilson
Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland 20892.
D G Johns
Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland 20892.
Online ISSN: 1540-9538
Print ISSN: 0022-1007
J Exp Med (1988) 168 (3): 1111–1125.
Citation
C F Perno, R Yarchoan, D A Cooney, N R Hartman, S Gartner, M Popovic, Z Hao, T L Gerrard, Y A Wilson, D G Johns; Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides.. J Exp Med 1 September 1988; 168 (3): 1111–1125. doi: https://doi.org/10.1084/jem.168.3.1111
Download citation file: